Hi Anzu Partners Community,

This is Michael Burychka, Co-Founder and CEO of Longview Innovation, and Jason Smith, Ph.D., Investment Manager and Managing Director at Longview. We’re excited to introduce ourselves and share that the Longview Innovation team has officially joined Anzu Partners.

At Longview, our mission has always been to create a new generation of companies, grounded in world-class scientific discovery, with the ability to disrupt existing industries or establish new ones. Over the years, we’ve had the privilege to work with visionary founders and leading research institutions, backing companies like Exyn Technologies, which developed pioneering autonomous navigation systems, and Cyrus Biotechnology, an AI driven protein therapeutics leader founded out of Nobel laureate David Baker’s lab at the University of Washington. These are just two examples of the technical innovation and commercial potential we’ve sought to support from the earliest stages.

Now, as part of Anzu, we’re thrilled to launch the North America University Innovations Fund, which will carry forward the Longview portfolio and extend our collective reach. As detailed in a feature on Venture Capital Journal*, we are confident that the combination of our talented teams and market reach will deliver scale and benefits to all of our stakeholders. We’ll also be opening a new Anzu office in Philadelphia, a city with leading academic institutions and a strong ecosystem for early-stage science ventures.

We’re joining Anzu because of a shared belief: that world-changing technologies deserve a platform that combines technical insight, operational rigor, and patient capital. Innovators are always looking forward and we see enormous opportunity ahead — and we’re excited to collaborate with this community to help shape the next generation of industrial and life science innovation.

Looking forward to building with you,
Michael & Jason 

*Requires a subscription to read

PORTFOLIO COMPANY UPDATES

EnCharge AI Announced EN100, First-of-its-Kind AI Accelerator for On-Device Computing

EnCharge AI announced the EnCharge EN100, the industry’s first AI accelerator built on precise and scalable analog in-memory computing. Designed to bring advanced AI capabilities to laptops, workstations, and edge devices, EN100 leverages transformational efficiency to deliver 200+ TOPS of total compute power within the power constraints of edge and client platforms such as laptops.

The launch was covered by IEEE Spectrum, VentureBeat, SiliconANGLE and more.

While the first round of EN100’s Early Access Program is currently full, interested developers and OEMs can sign up to learn more about the upcoming Round 2 Early Access Program, which provides a unique opportunity to gain a competitive advantage by being among the first to leverage EN100’s capabilities for commercial applications at env1.enchargeai.com.

NTxBio Announced New Manufacturing Facility in Plano, Texas

NTxBio (NTx), a company advancing the healthcare industry with next generation biomanufacturing solutions, announced that it will establish a biomanufacturing facility in Plano, Texas.

“We are thrilled to expand into our new facility in Plano as we grow to keep up with demand for NTx’s biomanufacturing platforms,” said NTx President and CEO Dr. Jamie Coffin in the press release. “Texas has a booming biotech community and an incredible talent pool in biological and chemical engineering, and we look forward to being part of that ecosystem. We’re excited to open our Plano production facility in partnership with the City of Plano and the State of Texas to augment our next-generation R&D facility in Rio Rancho, New Mexico. In both facilities, NTx will assemble cutting-edge biomanufacturing instruments that use domestically produced raw materials to advance treatments for cancer and rare diseases while bringing manufacturing and jobs back to the U.S.”

The news was covered by the Dallas Business Journal*, the Dallas Morning News*, Dallas Innovates and more.

CytoTronics Launched a Novel Cardiac Application for Pixel

CytoTronics, a pioneer of semiconductor-based platforms for discovery in cell biology, launched the next key offering in its Pixel application portfolio – a novel cardiac application. The first-of-its-kind, multi-modal application lets drug discovery scientists focused on cardiovascular disease and cardiotoxicology measure the electrical activity, contractility and structure of cardiomyocytes in a single assay at scale in 96-and 384-well plates.

With the FDA announcing plans to phase out animal testing requirements for drug development, Pixel’s Cardiac application offers a timely and powerful alternative.

To learn more about Pixel or CytoTronics’ Try Before You Buy program, visit cytotronics.com. You can also talk to their team at the American Heart Association Basic Cardiovascular Sciences Meeting, July 23–26 in Baltimore, MD.

BioSkryb Genomics and 1Cell.Ai Announced Strategic Partnership to Advance Single Cell Multi-omics Innovation

BioSkryb Genomics, a pioneer in single cell multi-omics, joined forces with 1Cell.Ai, a global leader in single cell precision diagnostics to co-develop and commercialize next-generation single cell multi-omic solutions. This collaboration will empower researchers and clinicians to detect and characterize rare mutations in single cells with unprecedented accuracy, facilitating breakthroughs in cancer research and enabling earlier detection and targeted therapy development.

This partnership combines BioSkryb’s single cell amplification and multi-omics chemistry with 1Cell.Ai’s OncoIncytes platform, creating a groundbreaking solution for analyzing rare cell populations such as circulating tumor cells (CTCs).

 Excision BioTherapeutics Announced New Publication Highlighting EBT-107

Excision BioTherapeutics, a biotechnology company developing CRISPR-based therapies to cure viral infectious diseases, announced publication of a preprint demonstrating proof-of-concept studies of EBT-107, a therapeutic candidate for chronic hepatitis B in bioRxiv.

EBT-107 is a CRISPR-based gene therapy that is being developed as a potential cure for chronic hepatitis B. The CRISPR/Cas gene editing system is formulated in lipid nanoparticles (LNPs) and is transiently activated to eliminate episomal and integrated HBV DNA copies by editing the viral DNA sequences at two well-conserved viral target sites.

The article entitled, “Multiplex Gene Editing Suppresses Random Integration of Hepatitis B Virus DNA in Chronically Infected Liver” is available online.

Excision also presented new data from its preclinical programs hepatitis B virus (HBV), EBT-107 and herpes simplex virus (HSV-1) keratitis, EBT-104 at the 2025 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, which took place May 13–17 in New Orleans, Louisiana.

ANZU PARTNERS UPDATES

Upcoming Events

BIO 2025 – June 16-19, 2025 – Boston, MA

The following Anzu portfolio companies will be in attendance:

• CytoTronics - Optics-free imaging for drug discovery
• Nirrin Technologies - Enabling real-time, non-invasive monitoring for advanced bioprocess control
• NTxBio - Pioneering decentralized and scalable mRNA manufacturing through synthetic biology

If you're attending BIO this year, don't miss the opportunity to connect with these teams at the forefront of biomanufacturing and bioprocess innovation.

Anzu representatives plan to attend the following events:

• Cleantech San Diego Innovation Showcase – June 11, 2025 – San Diego, CA
• Project InnerSpace New Mexico State Report Launch – June 12, 2025 – Santa Fe, NM
• GCV Symposium 2025 – June 17-19, 2025 – London

Please reach out to info@anzupartners.com if you’re interested in meeting with us at any of these events.

ADDITIONAL PC MEDIA COVERAGE

• Niron Magnetics was featured in an Axios* piece about growth amongst rare earth startups and in an Economist* piece about how to build strong magnets without rare earths. Niron was also mentioned in an opinion piece on The Hill about the urgent magnet problem in the US.
• EnCharge AI was featured in a piece in The Information* about AI chip startups. EnCharge’s CEO Naveen Verma was quoted in a piece in MIT Tech Review about AI’s energy usage.
• e-Zinc was named a 2025 “Coup de Couer” winner at the ChangeNOW 2025 awards in Paris. e-Zinc was also featured in a Betakit story about how the Ontario government is investing in homegrown companies.
• South 8 Technologies was featured by UC San Diego Today for a deep dive into its technology and origin story at UCSD.
• GelSight was featured in a New Electronics piece on humanoid robotics.
• Xendee’s CTO Michael Stadler appeared on the Currents Podcast to discuss energy management for data centers. He also appeared on an episode of the Energy Central podcast to discuss the microgrid boom. Michael also contributed a piece to EE Power on digital future proofing with microgrids in data centers.
• Voltaiq’s CEO Tal Sholklapper was a guest on the WardsAuto Podcast to discuss tracking battery quality.
• OTI Lumionics was featured in a Tom’s Guide piece on under display Face ID features on the iPhone 18 Pro.

*Requires a subscription to read

 Join Our Ecosystem 

Anzu Partners and our portfolio companies are growing, and we’re always looking for exceptional talent. Whether you're seeking new career opportunities or exploring ways to collaborate, we invite you to connect with us and become part of our network.

FOLLOW US

To stay up to date on the latest news from both Anzu and our portfolio companies, follow us on social media.

ABOUT ANZU PARTNERS

Anzu Partners is an investment firm that focuses on industrial and life science technology companies with the potential to transform their industries. Anzu works with entrepreneurs to develop and commercialize technological innovations by providing capital alongside deep expertise in business development, market positioning, intellectual property, global connectivity, and operations. For more information, please visit https://anzupartners. com/.